Aim 3 definition

Aim 3. Determine the causes of next generation institutional transnationalism Research has suggested a range of factors to explain transnational connectivity among the children of immigrants, including socialization (Xxxxxx and Xxxxx-Xxxxxxxx, 2002; Xxxxxxx, 2002; Xxxxxx and Xxxxxx, 2002; Xxxxxx et al., 2009; Xxxxxxxxxx, 2010; Soehl and Xxxxxxxxx, 2012; Xxxxxx and Xxxxxx, 2002), opportunity structures (Xxxxxx, 2002), and human attributes (Xxxxxx, 2002; Xxxxx, 2002; Xxxxxxx, 2002). This study explores the relevance of these factors in the transnational trajectories of next generation migrants, in order to identify the variables most conducive to institutional forms of transnational activity. It also goes further. First, it examines the significance of structural analysis (Xxxxxxx, 1988), which argues that social location – defined by the ties that connect individuals to one another in a social system – is the predominant factor controlling human behaviour, as this tends to determine access to opportunities and resources. Second, the study also examines individual agency: the strategies that individuals develop, and the actions they initiate, to realize their dreams, desires, and hopes.
Aim 3. To identify patient-level and dialysis facility-level factors that are associated with time to referral and time to waitlisting. In order to assess the effect of several factors on time to referral and waitlisting, a xxx regression model was used to evaluate sub-distributional hazards. This approach was desired in order to account for death as a competing event. In traditional survival analysis, if a subject is lost to follow-up, they are censored. This though assumes that at a given time point, those who remain under follow-up have the same future risk for the event of interest as those subjects no longer being followed or that have been censored (noninformative censoring) (42). This assumption is violated when death is used as a competing risk because if a patient dies, they no longer have the ability to experience the event of interest. Death as a competing risk was incorporated through the Fine and Grey method. This method is a compromise between completely censoring those who experienced a competing risk and retaining those who experienced a competing risk (46). For this analysis, deceased patients are retained in the risk set using conditional time-dependent weight. The weight of those patients who are artificially retained in the risk sets is gradually reduced according to the conditional probability of being under follow-up if the competing event had not occurred (47). This method helps to attenuate the overestimation bias that would otherwise occur with conventional time to event analysis. A covariate with a hazard ratio greater than one was interpreted as a being associated a higher probability of being referred or waitlisted and a hazard ratio less than one was interpreted as being associated with a lower probability. Additionally, the proportional hazard (PH) assumption was evaluated. The PH assumption requires that the hazard remains constant over time, or said in a different way, the hazard for one subject is proportional to the hazard of any other subject (43). For traditional Xxxxxx Xxxxx assumption, the PH can be visualized by graphing the log(- log(survival)) versus log(time). Given that competing risks were accounted for, the aforementioned graph cannot be calculated. Time-dependent covariates were used to assess the PH assumption. The significance of the product term was tested using the Wald statistic. The PH assumption was found to be violated for the variables: BMI, hypertension, Medicare, and age (though only when evaluating the PH ...
Aim 3. Right learning in the right place – secure coherent provision of higher education in Scotland in line with SFC’s statutory obligation. Background and baseline‌ 5 Equality outcome 1.3 from Equality Outcomes Progress Report April 2015 xxxx://xxx.xx.xx.xx/equality-diversity/about/strategy-action-plan 6 Equality outcome 1.6 from Equality Outcomes Progress Report April 2015 xxxx://xxx.xx.xx.xx/equality-diversity/about/strategy-action-plan The University has a strategic objective to equip our graduates with the expertise and graduate attributes they need to achieve their full potential within the global community. Central to that endeavour, the University teaches a fully comprehensive range of subjects, using our globally leading strengths in research to underpin and inform our teaching (Strategic Plan, page 9). The University works with employers, professional bodies, alumni and other stakeholders to ensure our degree programmes are responsive to need, producing graduates with socially and economically valuable attributes and expertise (Strategic Plan, page 9). The University collaborates with employers and appropriate sector bodies, such as the Association of Graduate Recruiters (Scotland) and the Scottish Higher Education Employability Forum (SHEEF) to facilitate direct interactions between students and business to enhance graduate employability. Over 9,000 job vacancies were advertised by our Careers Service in 2014/15, an increase of 8% on the previous year. For 2015/16 and 2016/17 we have a target of 5% annual growth. The Careers Service organises 12 career fairs across the academic year to support recruitment into a diverse range of employment sectors. This includes specialist events targeting the IT, engineering and creative sectors as well as generalist events which include finance, business, accounting, retail and other sectors. In 2016-17 we are introducing an additional strand to our Internships programme, specifically for the third sector with a target of 30 placements in the first year. 474 employers interacted with us through these events and we aim to reach 500 exhibitors in 2016/17. The University’s Student Employability Employers Forum and topical discussions through our Edinburgh Exchange events, ensure that external perspectives inform strategic thinking in relation to students’ employability and into our approach to learning and teaching. Outcome Action or target

Examples of Aim 3 in a sentence

  • Aim 3 - To provide a pleasant environment for those living, working and visiting the Borough.

  • Aim 3 needs more details on replication, exposure duration and intensity.

  • The Pulsewatch system will upload data when prompted by participants during Aim 3 or by a trained study staff member during the 14-day study visit.

  • Aim 3: Improve clinical evidence of the minimally invasive methodsImportant criteria to evaluate a biomarker are described in the ACCE model.

  • The activities of Aim 2 (study being conducted in HeH) and Aim 3 (N-of-1 Evaluation) are outlined in separate protocols.

  • We will decide on the final number of endotype-defining genes when the process yields a cross-validation misclassification error rate of < 10%.For the protein biomarker part of Aim 3, the cohort will be split 60:40 into a derivation and test set.

  • The endpoint of Aim 3 is generation of novel proteomic and transcriptomic endotypes.

  • Aim 3: understand that scientific knowledge and methods form the foundation of psychological practice through engagement in original and empirical investigations of psychological phenomena.

  • We will assess the cost, cost threshold, and cost-utility of the CCRP model (Aim 3).

  • Aim 3: Efficient and Effective Operations Goal 1: The District will hire and retain a high performing workforce.Goal 2: The District will practice responsible fiscal management.


More Definitions of Aim 3

Aim 3. To provide recommendations as to how the Justinien University Hospital in Cap- Haïtien, Haiti, can address the gaps in sexual and reproductive health and family planning among their patients. Significance Statement‌ The findings from this study have the potential to be utilized for future public health programming and training, focusing on interventions to adequately and effectively care for women within this vulnerable subpopulation. While the entirety of the study focused on a wide range of sexual and reproductive health topics, the methodology could be adapted for future research studies, such as altering participant criteria or implementing qualitative questions around characteristics associated with attempt of a self-managed abortion, within other reproductive care providers in Haiti. The findings may also be useful to providers in other countries that have similar populations and health systems. These data can be used to further support and contribute to the small, yet growing body of literature explicitly addressing unsafe abortion in Haiti. It is especially pertinent for the Haitian Ministry of Health and the Justinien University Hospital to address areas for intervention and reproductive health gaps that may be evident from the data. Documenting the utilization and underutilization of critical reproductive health resources and services illuminates a tangible gap that can be filled with proven methods to reduce unintended pregnancy, maternal and infant mortality, and increase access to contraception and postabortion services.
Aim 3. To assess the frequency of pathogenic FMR1 sequence variants in a developmentally delayed clinical population Although the current clinical application of FMR1 sequencing is largely limited to fragile X-like patients, it is unclear if point mutations in FMR1 would manifest in this phenotype. Thus, to investigate a less specific phenotype, we used a pooled-template method to sequence FMR1 in 963 developmentally delayed males who had been referred to our clinical laboratory for fragile X testing. In the process, we were also able to create a more complete catalogue of normal variants in FMR1.
Aim 3. To evaluate the intervention conditions by comparing outcome risk measures (HIV disclosure, HIV testing, condom use, drug and/or alcohol use before sex, and depressive and/or anxiety symptomatology) at 2 time points for 5 study conditions.

Related to Aim 3

  • Opium poppy means the plant of the species Papaver somniferum L., except its seeds.

  • Cannabinoid edible means food or potable liquid into which a cannabinoid concentrate, cannabinoid extract or dried marijuana leaves or flowers have been incorporated.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • IPPF means the indigenous peoples planning framework for the Investment Program, including any update thereto, agreed between the Borrower and ADB and incorporated by reference in the FFA;

  • Clinical peer means a physician or other health care professional who holds a non-restricted license in a state of the United States and in the same or similar specialty as typically manages the medical condition, procedure or treatment under review.

  • Phase 4 Clinical Trial means a Clinical Study in any country which is conducted after Regulatory Approval of a product has been obtained from an appropriate Regulatory Authority, consisting of trials conducted voluntarily for enhancing marketing or scientific knowledge of an approved indication and trials conducted due to request or requirement of a Regulatory Authority.

  • Dynamic driving task means the same as that term is defined in Section 41-26-102.1.

  • AIMA means the Alternative Investment Management Association.

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

  • coronavirus means severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);

  • Anaerobic digestion ’ means a controlled process involving microbial decomposition of organic matter in the absence of oxygen ;

  • Biomethane means biogas that meets pipeline quality natural gas standards.

  • Nitrogen oxides means nitric oxide and nitrogen dioxide, expressed as nitrogen dioxide (NO2);

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Air-purifying respirator means a respirator with an air-purifying filter, cartridge, or canister that removes specific air contaminants by passing ambient air through the air-purifying element.

  • Clinical Trials means a controlled study in humans of the safety or efficacy of a Product, and includes, without limitation, such clinical trials as are designed to support expanded labeling or to satisfy the requirements of an Agency in connection with any Product Approval and any other human study used in research and Development of a Product.

  • CDDP means "Community Developmental Disabilities Program".

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • MHRD means “Ministry of Human Resource Development, Govt. of India.”

  • EPFO means Employees' Provident Fund Organization

  • Mobile crisis outreach team means a crisis intervention service for minors or families of minors experiencing behavioral health or psychiatric emergencies.

  • MCIP means (i) the joint county industrial park established pursuant to the terms of the MCIP Agreement and (ii) any joint county industrial park created pursuant to a successor park agreement delivered by the County and a partner county in accordance with Section 4-1-170 of the MCIP Act, or any successor provision, with respect to the Project.

  • EPG means electronic program guide maintained by a DPO on its Digital Distribution Platform which lists the television channels and programs, and scheduling and programming information therein and includes any enhanced electronic guide that allows Subscribers to navigate and select such available channels and programs.

  • Clean coal technology demonstration project means a project using funds appropriated under the heading “Department of Energy—Clean Coal Technology,” up to a total amount of $2,500,000,000 for commercial demonstration of clean coal technology, or similar projects funded through appropriations for the Environmental Protection Agency. The federal contribution for a qualifying project shall be at least 20 percent of the total cost of the demonstration project.

  • SPMCIL means Security Printing and Minting Corporation Limited"SPMCIL" means Security Printing and Minting Corporation Limited